TP53 and neoplasm: Related studies using tumour cell lines tested for their p53 status have shown that mutations of p53 correlate with drug resistance to a wide spectrum of anticancer agents, including topo II inhibitors (O'Connor et al, 1997; Sirvent et al, 2001).